Skip to main content
TipRanks
Go Ultimate75% OFF

GENinCode UK Ltd. (9PL) AI Stock Analysis

1 Followers
DE:9PL

GENinCode UK Ltd.

(Frankfurt:9PL)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Accelerating Revenue GrowthThe acceleration in revenue growth indicates improving commercial traction and broader adoption of the company’s diagnostic offering. If sustained, stronger top-line expansion can improve operating leverage, support investment in the business, and help the company progress toward a more viable scale.
Negative Factors
Deep and Persistent UnprofitabilityThe depth and persistence of losses show that current revenue remains far below the level needed to cover the company’s cost base. Without a material improvement in operating efficiency or scale, ongoing losses can consume capital, restrict investment capacity, and delay a credible path to profitability.

GENinCode UK Ltd. (9PL) vs. iShares MSCI Germany ETF (EWG)

-100%0%100%200%300%400%DE:9PL-44.44%EWG+7.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 4.52M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.4
Beta (1Y)
12.87
Revenue Growth
-13.75%
EPS Growth
44.57%
Country
Germany
Employees
44
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

GENinCode UK Ltd. Business Overview & Revenue Model

Company Description

GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology...

GENinCode UK Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:9PL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:GDRGB:GDR49NeutralGBP 14.45M-0.82-1044.57%―65.60%74.84%
GB:CLBXGB:CLBX48NeutralGBP 6.82M-0.49-104.73%―-56.10%41.10%
GB:ABDXGB:ABDX46NeutralGBP 21.48M-15.45-34.31%―30.42%43.16%
GB:RENXGB:RENX44NeutralGBP 35.87M-3.33675.00%―――
GB:OBDGB:OBD40UnderperformGBP 14.79M-0.28-451.74%―33.37%86.41%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%DE:9PLGB:CLBXGB:GDRGB:OBDGB:RENXGB:ABDXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:9PL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:9PLGENinCode UK Ltd.0.01-0.01-44.44%
GB:CLBXANGLE plc0.60-1.15-65.71%
GB:GDRGenedrive plc0.90-0.14-13.21%
GB:OBDOxford BioDynamics0.11-0.17-60.71%
GB:RENXRenalytix Plc OTC5.35-1.40-20.74%
GB:ABDXAbingdon Health PLC8.501.0013.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.